{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:05:55Z","timestamp":1790287555153,"version":"4.1.0"},"reference-count":62,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T00:00:00Z","timestamp":1706313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Discovery"],"published-print":{"date-parts":[[2024,4,2]]},"DOI":"10.1080\/17460441.2024.2306843","type":"journal-article","created":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T05:30:01Z","timestamp":1706419801000},"page":"393-402","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":21,"title":["Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7880-2316","authenticated-orcid":false,"given":"Violaine","family":"Plant\u00e9-Bordeneuve","sequence":"first","affiliation":[{"name":"Department of Neurology, Henri Mondor University Hospital, AP-HP, Cr\u00e9teil, France"},{"name":"Mondor Biomedical Research Institute \u2013 IMRB, INSERM, U955 Team 10 \u201cBiology of the Neuromuscular System\u201d, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Perrain","sequence":"additional","affiliation":[{"name":"Department of Neurology, Henri Mondor University Hospital, AP-HP, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,1,27]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-327909"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8708-4"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2023.2178891"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24519"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac119"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000574"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318248df18"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200203150-00015"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ea15d4"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1121005109"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182661eb1"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-7051-7"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8337-3"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8064-9"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126526"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2027"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.283815"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2019.11.024"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12519"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-041217-010829"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114432"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3802"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716793"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11276-8"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2019.1685487"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2017.1374946"},{"key":"e_1_3_5_30_1","unstructured":"MD RHF. 24 month open label study of the tolerability and efficacy of an antisense oligonucleotide (inotersen) in patients with transthyretin (TTR) amyloid cardiomyopathy. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03702829."},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00577-7"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208760"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1553"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30368-9"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2023.2232520"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S359851"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300757"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2309308"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1974"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2020.0852"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2337"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2091985"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00522-4"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvdsp.2022.10.056"},{"key":"e_1_3_5_46_1","unstructured":"Alnylam Pharmaceuticals. HELIOS-B: a phase 3 randomized double-blind placebo-controlled multicenter study to evaluate the efficacy and safety of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy (ATTR amyloidosis with cardiomyopathy). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04153149"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01765-5"},{"key":"e_1_3_5_48_1","unstructured":"EMA. Amvuttra. European Medicines Agency. 2022. Available from. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/amvuttra"},{"key":"e_1_3_5_49_1","unstructured":"National Institute for Health and Care Excellence (NICE). Evidence | vutrisiran for treating hereditary transthyretin-related amyloidosis | guidance. NICE; 2023. Available from: https:\/\/www.nice.org.uk\/guidance\/ta868\/evidence"},{"key":"e_1_3_5_50_1","unstructured":"de Sant\u00e9 HA. AMVUTTRA (vutrisiran) - first evaluation. Haute Aut. Sant\u00e9. Available from: https:\/\/www.has-sante.fr\/jcms\/p_3402366\/fr\/amvuttra-vutrisiran-amylose-hereditaire-a-transthyretine."},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01943-z"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15468"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.18688"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116424"},{"key":"e_1_3_5_55_1","unstructured":"Ionis Pharmaceuticals Inc. A phase 3 global double-blind randomized placebo-controlled study to evaluate the efficacy and safety of ION-682884 in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR CM). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04136171"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107454"},{"key":"e_1_3_5_57_1","unstructured":"Intellia Therapeutics. Phase 1 two-part (open-label single ascending dose (part 1) and open-label single dose expansion (part 2)) study to evaluate safety tolerability pharmacokinetics and pharmacodynamics of NTLA-2001 in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) and patients with transthyretin amyloidosis-related cardiomyopathy (ATTR-CM) Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04601051"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000202920"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.15087"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2215925"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2023.149397"},{"key":"e_1_3_5_62_1","unstructured":"Alnylam Pharmaceuticals. A phase 1 randomized double-blind placebo controlled single-ascending dose study to evaluate the safety tolerability pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneously administered ALN-TTRSC04 in healthy subjects. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05661916"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303765"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2023.2263620"}],"container-title":["Expert Opinion on Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17460441.2024.2306843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T17:25:24Z","timestamp":1727198724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17460441.2024.2306843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,27]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,2]]}},"alternative-id":["10.1080\/17460441.2024.2306843"],"URL":"https:\/\/doi.org\/10.1080\/17460441.2024.2306843","relation":{},"ISSN":["1746-0441","1746-045X"],"issn-type":[{"value":"1746-0441","type":"print"},{"value":"1746-045X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-10-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}